NO3106463T3 - - Google Patents
Info
- Publication number
- NO3106463T3 NO3106463T3 NO16166461A NO16166461A NO3106463T3 NO 3106463 T3 NO3106463 T3 NO 3106463T3 NO 16166461 A NO16166461 A NO 16166461A NO 16166461 A NO16166461 A NO 16166461A NO 3106463 T3 NO3106463 T3 NO 3106463T3
- Authority
- NO
- Norway
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10761608P | 2008-10-22 | 2008-10-22 | |
| EP13197815.7A EP2725028B1 (en) | 2008-10-22 | 2009-10-21 | Substituted pyrazolo[1,5-]pyrimidine compounds as intermediates in the synthesis of TRK kinase inhibitors |
| EP09740245.7A EP2350071B1 (en) | 2008-10-22 | 2009-10-21 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO3106463T3 true NO3106463T3 (no) | 2018-07-28 |
Family
ID=41328903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO16166461A NO3106463T3 (no) | 2008-10-22 | 2009-10-21 | |
| NO2020004C NO2020004I1 (no) | 2008-10-22 | 2020-03-10 | Larotrektinib og/eller farmasøytisk akseptable salter derav, særlig larotrektinibsulfat inkludert larotrektinibhydrogensulfat |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO2020004C NO2020004I1 (no) | 2008-10-22 | 2020-03-10 | Larotrektinib og/eller farmasøytisk akseptable salter derav, særlig larotrektinibsulfat inkludert larotrektinibhydrogensulfat |
Country Status (39)
| Country | Link |
|---|---|
| US (11) | US8513263B2 (no) |
| EP (4) | EP3106463B3 (no) |
| JP (5) | JP5600111B2 (no) |
| KR (5) | KR101652189B1 (no) |
| CN (2) | CN102264736B (no) |
| AR (2) | AR074052A1 (no) |
| AU (1) | AU2009308465B2 (no) |
| BR (1) | BRPI0919873B8 (no) |
| CA (1) | CA2741313C (no) |
| CL (1) | CL2011000880A1 (no) |
| CO (1) | CO6440551A2 (no) |
| CR (1) | CR20110261A (no) |
| CY (4) | CY1118199T1 (no) |
| DK (4) | DK3372605T3 (no) |
| ES (4) | ES2456346T3 (no) |
| HK (2) | HK1160640A1 (no) |
| HR (3) | HRP20211722T1 (no) |
| HU (4) | HUE037716T2 (no) |
| IL (3) | IL212341A0 (no) |
| LT (4) | LT3372605T (no) |
| LU (1) | LUC00150I2 (no) |
| ME (1) | ME03010B (no) |
| MX (1) | MX2011004204A (no) |
| MY (1) | MY169791A (no) |
| NL (1) | NL301033I2 (no) |
| NO (2) | NO3106463T3 (no) |
| NZ (1) | NZ592809A (no) |
| PL (4) | PL2725028T3 (no) |
| PT (4) | PT2350071E (no) |
| RS (3) | RS62869B1 (no) |
| RU (1) | RU2018131134A (no) |
| SG (3) | SG196855A1 (no) |
| SI (4) | SI3372605T1 (no) |
| SM (2) | SMT201800244T1 (no) |
| TR (1) | TR201807039T4 (no) |
| TW (4) | TWI670272B (no) |
| UA (1) | UA106054C2 (no) |
| UY (1) | UY32192A (no) |
| WO (1) | WO2010048314A1 (no) |
Families Citing this family (135)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2350075E (pt) * | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| DK3372605T3 (da) | 2008-10-22 | 2021-11-22 | Array Biopharma Inc | Substituerede pyrazol[1,5-a]pyrimidinforbindelser som trk-kinasehæmmere |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| RU2735545C2 (ru) * | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| WO2012034095A1 (en) * | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| ES2551592T3 (es) | 2011-02-25 | 2015-11-20 | Novartis Ag | Pirazolo[1,5-a]piridinas como inhibidores de TRK |
| DK2712358T3 (en) * | 2011-05-13 | 2017-02-06 | Array Biopharma Inc | PYRROLIDINYLUREA, PYRROLIDINYLTHIOUREA AND PYRROLIDINYLGUANIDE IN COMPOUNDS AS TRKA-KINASE INHIBITORS |
| EP2791138B1 (en) * | 2011-12-12 | 2018-06-06 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors |
| KR101965025B1 (ko) * | 2012-03-09 | 2019-04-02 | 렉시컨 파마슈티컬스 인코퍼레이티드 | 피라졸로[1,5-a]피리미딘계 화합물, 그를 포함하는 조성물 및 그의 사용 방법 |
| WO2014078417A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9828360B2 (en) | 2012-11-13 | 2017-11-28 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| WO2014078328A1 (en) * | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| PL2920166T3 (pl) | 2012-11-13 | 2017-05-31 | Array Biopharma, Inc. | Bicykliczne związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny przydatne w leczeniu bólu |
| PL2922844T3 (pl) | 2012-11-13 | 2018-06-29 | Array Biopharma, Inc. | N-pirolidynyl, n’-pirazolilowe związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny jako inhibitory kinazy trka |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| CA2897200C (en) | 2013-01-14 | 2021-07-06 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| EP4186897A1 (en) | 2013-01-15 | 2023-05-31 | Incyte Holdings Corporation | Pyridinecarboxamide compound useful as pim kinase inhibitor |
| JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
| TW201542550A (zh) * | 2013-09-06 | 2015-11-16 | Lexicon Pharmaceuticals Inc | 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法 |
| SMT202300008T1 (it) | 2014-01-24 | 2023-03-17 | Turning Point Therapeutics Inc | Diaril macrociclici come modulatori di protein chinasi |
| CN108892661B (zh) * | 2014-02-07 | 2023-03-14 | 艾克赛特赫拉制药有限责任公司 | 治疗化合物和组合物 |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| EP3154959B1 (en) | 2014-05-15 | 2019-07-10 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
| US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
| LT3699181T (lt) * | 2014-11-16 | 2023-05-10 | Array Biopharma, Inc. | Kristalinė (s)-n-(5-((r)-2-(2,5-difluorfenil)-pirolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3 -hidroksipirolidino-1-karboksamido vandenilio sulfato forma |
| JP6744309B2 (ja) | 2014-12-02 | 2020-08-19 | イグニタ，インコーポレイテッド | 神経芽細胞腫の治療のための併用 |
| EP4420732A3 (en) | 2014-12-15 | 2024-11-27 | CMG Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| EP3268367B8 (en) * | 2015-03-12 | 2022-11-16 | Merck Sharp & Dohme LLC | Carboxamide inhibitors of irak4 activity |
| WO2016144846A1 (en) * | 2015-03-12 | 2016-09-15 | Merck Sharp & Dohme Corp. | Pyrazolopyrimidine inhibitors of irak4 activity |
| WO2016196141A1 (en) * | 2015-05-29 | 2016-12-08 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
| US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
| EP3303631A1 (en) | 2015-06-01 | 2018-04-11 | Loxo Oncology Inc. | Methods of diagnosing and treating cancer |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| EP4397665A3 (en) | 2015-07-06 | 2024-08-21 | Turning Point Therapeutics, Inc. | Diaryl macrocycle polymorph |
| JP6816100B2 (ja) | 2015-07-16 | 2021-01-20 | アレイ バイオファーマ、インコーポレイテッド | ＲＥＴキナーゼ阻害物質としての置換ピラゾロ［１，５−ａ］ピリジン化合物 |
| DK3733187T3 (da) | 2015-07-21 | 2025-01-02 | Turning Point Therapeutics Inc | Chiral diarylmakrocyklus og anvendelse deraf i behandling af cancer |
| JP6877407B2 (ja) | 2015-08-26 | 2021-05-26 | ブループリント メディシンズ コーポレイション | Ｎｔｒｋ関連障害の治療に有用な化合物および組成物 |
| TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Ｐｉｍ激酶抑制劑之鹽 |
| WO2017059251A1 (en) | 2015-10-02 | 2017-04-06 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
| EP3368039A1 (en) * | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017087778A1 (en) | 2015-11-19 | 2017-05-26 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| MX2018007266A (es) | 2015-12-18 | 2018-11-09 | Ignyta Inc | Combinaciones para el tratamiento del cancer. |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| JP7057343B2 (ja) * | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | 小児癌の処置方法 |
| HRP20241282T1 (hr) | 2016-04-04 | 2024-12-06 | Loxo Oncology, Inc. | Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid |
| US11214571B2 (en) * | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
| RU2019105587A (ru) | 2016-07-28 | 2020-08-28 | Тёрнинг Поинт Терапьютикс, Инк. | Макроциклические ингибиторы киназ |
| JOP20190077A1 (ar) | 2016-10-10 | 2019-04-09 | Array Biopharma Inc | مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| DK3533796T3 (da) | 2016-10-28 | 2021-11-08 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Aminopyrazolopyrimidinforbindelse anvendt som neutrof faktor tyrosinkinasereceptor inhibitor |
| CN108003161B (zh) * | 2016-10-28 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 神经营养因子酪氨酸激酶受体抑制剂 |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| CN110267960B (zh) | 2017-01-18 | 2022-04-26 | 阿雷生物药品公司 | 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物 |
| WO2018136663A1 (en) | 2017-01-18 | 2018-07-26 | Array Biopharma, Inc. | Ret inhibitors |
| TWI808958B (zh) | 2017-01-25 | 2023-07-21 | 美商特普醫葯公司 | 涉及二芳基巨環化合物之組合療法 |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| AU2018302170B2 (en) | 2017-07-19 | 2024-02-29 | Ignyta, Inc. | Pharmaceutical compositions comprising entrectinib |
| WO2019023417A1 (en) | 2017-07-28 | 2019-01-31 | Tp Therapeutics, Inc. | MACROCYCLIC COMPOUNDS AND USES THEREOF |
| US11344553B2 (en) | 2017-08-11 | 2022-05-31 | Teligene Ltd. | Substituted pyrazolopyrimidines useful as kinases inhibitors |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| CN110945000B (zh) * | 2017-08-23 | 2021-09-03 | 正大天晴药业集团股份有限公司 | 含有氨基吡唑并嘧啶的大环化合物及其药物组合物和用途 |
| CN107556226B (zh) * | 2017-09-21 | 2020-06-30 | 苏州明锐医药科技有限公司 | 一种拉曲替尼中间体的制备方法 |
| CN107445879B (zh) * | 2017-09-21 | 2020-07-24 | 苏州立新制药有限公司 | 拉曲替尼中间体的制备方法 |
| TWI791053B (zh) | 2017-10-10 | 2023-02-01 | 美商亞雷生物製藥股份有限公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物 |
| TWI812649B (zh) | 2017-10-10 | 2023-08-21 | 美商絡速藥業公司 | 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物 |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
| US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| EP3684770A1 (en) | 2017-10-31 | 2020-07-29 | Assia Chemical Industries Ltd | Salts and solid state forms of larotrectinib |
| EP3706749B1 (en) | 2017-11-10 | 2024-03-13 | Angex Pharmaceutical, Inc. | Macrocyclic compounds as trk kinase inhibitors and uses thereof |
| CN107987082B (zh) * | 2017-11-14 | 2019-09-20 | 苏州东南药业股份有限公司 | 一种Larotrectinib的制备方法及其中间体 |
| AR113922A1 (es) | 2017-12-08 | 2020-07-01 | Incyte Corp | Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas |
| PT4053128T (pt) * | 2017-12-15 | 2024-10-15 | Biohaven Therapeutics Ltd | Derivados de 5-(2-(2,5-difluorofenil)pirrolidin-1-il)-3-(1h-pirazol-1-il)pirazolo[1,5-a]pirimidina e compostos relacionados como inibidores de trk cinase para tratamento de cancro |
| KR20200101358A (ko) | 2017-12-19 | 2020-08-27 | 터닝 포인트 테라퓨틱스, 인크. | 질병 치료용 대환식 화합물 |
| CN109456331B (zh) * | 2017-12-22 | 2020-06-05 | 深圳市塔吉瑞生物医药有限公司 | 一种取代的吡唑并[1,5-a]嘧啶化合物及其药物组合物及用途 |
| CA3087354C (en) | 2018-01-18 | 2023-01-03 | Array Biopharma Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| EP3740490A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors |
| TW201932464A (zh) | 2018-01-18 | 2019-08-16 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物 |
| WO2019144885A1 (zh) | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡唑并[1,5-a]嘧啶类的大环化合物 |
| TW201932472A (zh) * | 2018-01-30 | 2019-08-16 | 大陸商上海吉倍生物技術有限公司 | 具有大環分子結構的化合物及其用途 |
| AU2019233204B2 (en) * | 2018-03-14 | 2022-02-03 | Fochon Biosciences, Ltd. | Substituted (2-azabicyclo (3.1.0) hexan-2-yl) pyrazolo (1, 5-a) pyrimidine and imidazo (1, 2-b) pyridazine compounds as TRK kinases inhibitors |
| CN110305138B (zh) * | 2018-03-27 | 2021-04-23 | 海创药业股份有限公司 | 一种治疗癌症的化合物及其用途 |
| WO2019191659A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
| CN112004975A (zh) | 2018-03-30 | 2020-11-27 | 住友重机械工业株式会社 | 施工机械的驾驶支援系统、施工机械 |
| EP3786167B1 (en) | 2018-04-25 | 2024-08-21 | Primegene (Beijing) Co., Ltd. | Diaryl macrocyclic compound and pharmaceutical composition, and use thereof |
| CN110294761B (zh) * | 2018-06-08 | 2020-09-08 | 南京雷正医药科技有限公司 | 作为Trk激酶抑制剂的取代的吡唑并[1,5-a]嘧啶化合物 |
| CN110627812B (zh) | 2018-06-25 | 2022-10-11 | 北京诺诚健华医药科技有限公司 | 作为trk抑制剂的杂环化合物 |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| KR20210075071A (ko) | 2018-08-14 | 2021-06-22 | 오스테오큐씨 인코포레이티드 | 피롤로-디피리딘 화합물 |
| WO2020037001A1 (en) | 2018-08-14 | 2020-02-20 | Osteoqc Inc. | FLUORO β-CARBOLINE COMPOUNDS |
| CN110857304B (zh) * | 2018-08-24 | 2021-05-18 | 北京富龙康泰生物技术有限公司 | Trk抑制剂、其制备方法和用途 |
| US11952364B2 (en) | 2018-09-03 | 2024-04-09 | Tyligand Bioscience (Shanghai) Limited | TRK inhibitors useful as anticancer drugs |
| CA3111984A1 (en) | 2018-09-10 | 2020-03-19 | Array Biopharma Inc. | Fused heterocyclic compounds as ret kinase inhibitors |
| CN112955453B (zh) * | 2018-09-29 | 2022-04-19 | 山东绿叶制药有限公司 | 作为选择性Trk抑制剂的吡唑并嘧啶衍生物 |
| CN111039947A (zh) * | 2018-10-15 | 2020-04-21 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
| CN111171019A (zh) | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| CN111171020A (zh) | 2018-11-13 | 2020-05-19 | 上海轶诺药业有限公司 | 一类六元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途 |
| CN109232582B (zh) * | 2018-11-28 | 2021-02-05 | 安礼特（上海）医药科技有限公司 | 拉洛替尼硫酸氢盐晶型及其制备和应用 |
| CN111269233A (zh) * | 2018-12-05 | 2020-06-12 | 上海轶诺药业有限公司 | 一类咪唑并芳环类化合物的制备和应用 |
| CN109608464B (zh) * | 2018-12-12 | 2021-09-24 | 上海健康医学院 | 一种放射性碘标记Larotrectinib化合物及其制备方法和应用 |
| CN109705124B (zh) * | 2018-12-14 | 2021-09-24 | 上海健康医学院 | 一种放射性氟标记Larotrectinib化合物及其制备方法 |
| US20220041579A1 (en) | 2018-12-19 | 2022-02-10 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of fgfr tyrosine kinases |
| CN113490666A (zh) | 2018-12-19 | 2021-10-08 | 奥瑞生物药品公司 | 作为fgfr酪氨酸激酶的抑制剂的取代的吡唑并[1,5-a]吡啶化合物 |
| CN111362946A (zh) * | 2018-12-25 | 2020-07-03 | 上海度德医药科技有限公司 | 一种药物化合物及其组合物和应用 |
| CN109942574B (zh) * | 2019-01-11 | 2022-04-01 | 成都阿奇生物医药科技有限公司 | 天奇替尼及其制备方法和用途 |
| CN109942582B (zh) * | 2019-03-15 | 2020-12-01 | 上海健康医学院 | 一种靶向原肌球蛋白激酶trk融合蛋白的pet探针及其合成与应用 |
| JP7209415B2 (ja) | 2019-03-19 | 2023-01-20 | セントラル チャイナ ノーマル ユニバーシティ | ピラゾロピリミジン化合物、医薬組成物、及びその使用 |
| JP2022526713A (ja) | 2019-03-21 | 2022-05-26 | オンクセオ | がんの処置のための、キナーゼ阻害剤と組み合わせたＤｂａｉｔ分子 |
| CN111848626B (zh) * | 2019-04-30 | 2021-11-30 | 江苏柯菲平医药股份有限公司 | Trk激酶抑制剂及其用途 |
| US20200398978A1 (en) * | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| CA3145641A1 (en) * | 2019-08-08 | 2021-02-11 | Didier Rognan | Trkb positive allosteric modulators |
| CN110804059B (zh) * | 2019-09-30 | 2024-03-12 | 郑州泰基鸿诺医药股份有限公司 | 氨基甲酸酯类化合物、药物组合物及其应用 |
| CN110643672A (zh) * | 2019-10-15 | 2020-01-03 | 西安交通大学 | 高表达TrkB作为新型靶点在抑制胰腺癌转移方面的医药用途 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| CN112812118A (zh) * | 2019-11-18 | 2021-05-18 | 上海轶诺药业有限公司 | 一类蛋白受体激酶抑制剂的制备和应用 |
| CN111138437B (zh) * | 2019-12-04 | 2021-03-05 | 杭州华东医药集团新药研究院有限公司 | 取代的吡唑并[1,5-a]嘧啶氨基酸衍生物及其用途 |
| CN112979654B (zh) * | 2019-12-16 | 2024-03-19 | 赛诺哈勃药业（成都）有限公司 | 杂芳基稠环化合物、其制备方法及应用 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021187878A1 (ko) * | 2020-03-17 | 2021-09-23 | 제이투에이치바이오텍 주식회사 | 변이성 trk 융합 단백질 억제용 화합물, 이의 의약 용도 및 제조 방법 |
| CN113563343B (zh) * | 2020-07-27 | 2022-05-24 | 杭州邦顺制药有限公司 | 取代的吡唑并[1,5-a]嘧啶化合物及其用途 |
| WO2022168115A1 (en) | 2021-02-05 | 2022-08-11 | Mylan Laboratories Limited | A process for the preparation of larotrectinib or its salts |
| CN116120322B (zh) * | 2021-11-15 | 2024-11-15 | 石药集团中奇制药技术（石家庄）有限公司 | 氮杂稠环酰胺类化合物的盐、其结晶形式及其用途 |
| CN116162089B (zh) * | 2022-03-23 | 2023-10-31 | 南京知和医药科技有限公司 | 嘧啶基抗病毒化合物的制备与使用方法 |
| CN114907315B (zh) * | 2022-05-17 | 2023-09-12 | 重庆医科大学 | Selitrectinib中间体的合成方法 |
| CN117343064B (zh) * | 2022-07-05 | 2024-04-16 | 南京知和医药科技有限公司 | 一种具有抗病毒作用的嘧啶衍生物的制备与应用 |
| WO2024023836A1 (en) | 2022-07-27 | 2024-02-01 | Mylan Laboratories Limited | Polymorphic form of larotrectinib sulfate |
| EP4382529A1 (en) | 2022-12-07 | 2024-06-12 | Bayer Consumer Care AG | A process for preparing pure (3s)-pyrrolidin-3-ol and pure (3s)-pyrrolidin-3-ol hydrochloride |
| WO2024242416A1 (ko) * | 2023-05-22 | 2024-11-28 | 주식회사 셀러스 | 신규한 cdk7 억제 화합물 및 이의 용도 |
Family Cites Families (200)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1017286A (en) | 1909-03-01 | 1912-02-13 | Du Pont Powder Co | Apparatus for treating explosive powder. |
| US1001160A (en) | 1910-04-05 | 1911-08-22 | Paul A Otto | Aerodrome. |
| US1004709A (en) | 1910-05-20 | 1911-10-03 | Albert E Yerkes | Spraying device. |
| US1013712A (en) | 1911-06-03 | 1912-01-02 | Alfred D Williams | Tie and rail-fastener. |
| NZ234143A (en) | 1989-06-28 | 1991-10-25 | Mcneil Ppc Inc | Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents |
| GB9212308D0 (en) | 1992-06-10 | 1992-07-22 | Ici Plc | Therapeutic compositions |
| NZ276885A (en) | 1993-11-30 | 1999-08-30 | Searle & Co | Substituted pyrazolyl-benzenesulphonamide derivatives, preparation and pharmaceutical compositions thereof |
| US5844092A (en) | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
| US5877016A (en) | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
| US5430021A (en) | 1994-03-18 | 1995-07-04 | Pharmavene, Inc. | Hydrophobic drug delivery systems |
| US6458811B1 (en) | 1996-03-26 | 2002-10-01 | Eli Lilly And Company | Benzothiophenes formulations containing same and methods |
| CA2206201A1 (en) | 1996-05-29 | 1997-11-29 | Yoshiaki Isobe | Pyrazole derivatives and their pharmaceutical use |
| JPH1020683A (ja) | 1996-07-05 | 1998-01-23 | Fuji Xerox Co Ltd | 画像形成装置 |
| JP3898296B2 (ja) * | 1996-08-28 | 2007-03-28 | ポーラ化成工業株式会社 | ピロロピラゾロピリミジン化合物及びこれを有効成分とする医薬 |
| KR100389192B1 (ko) | 1997-04-25 | 2003-06-27 | 다케다 야쿠힌 고교 가부시키가이샤 | 축합 피리다진 유도체, 그것의 제조 방법 및 용도 |
| JP2002535253A (ja) | 1999-01-21 | 2002-10-22 | ブリストル−マイヤーズ スクイブ カンパニー | ｒａｓファルネシルトランスフェラーゼインヒビターおよびスルホブチルエーテル−７−β−シクロデキストリンまたは２−ヒドロキシプロピル−β−シクロデキストリンの複合体、ならびにその製造方法 |
| UA74546C2 (en) | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6534085B1 (en) | 1999-09-23 | 2003-03-18 | Bioresponse L.L.C. | Phytochemicals for promoting weight loss |
| WO2001098361A2 (en) | 2000-06-22 | 2001-12-27 | Genentech, Inc. | Agonist anti-trk-c monoclonal antibodies |
| GB0028575D0 (en) | 2000-11-23 | 2001-01-10 | Elan Corp Plc | Oral pharmaceutical compositions containing cyclodextrins |
| US20040067999A1 (en) | 2000-12-22 | 2004-04-08 | Block Michael Howard | Carbazole derivatives and their use as neuropeptide y5 receptor ligands |
| TWI312347B (en) | 2001-02-08 | 2009-07-21 | Eisai R&D Man Co Ltd | Bicyclic nitrogen-containing condensed ring compounds |
| NZ544410A (en) | 2001-05-30 | 2008-04-30 | Genentech Inc | Anti-ngf antibodies for the treatment of various disorders |
| US7101572B2 (en) | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US20030199525A1 (en) | 2002-03-21 | 2003-10-23 | Hirst Gavin C. | Kinase inhibitors |
| JP4500055B2 (ja) * | 2002-04-23 | 2010-07-14 | 塩野義製薬株式会社 | ピラゾロ［１，５−ａ］ピリミジン誘導体およびそれを含有するＮＡＤ（Ｐ）Ｈオキシダーゼ阻害剤 |
| US7449488B2 (en) * | 2002-06-04 | 2008-11-11 | Schering Corporation | Pyrazolopyrimidines as protein kinase inhibitors |
| US6982253B2 (en) | 2002-06-05 | 2006-01-03 | Supergen, Inc. | Liquid formulation of decitabine and use of the same |
| JP4024624B2 (ja) | 2002-08-26 | 2007-12-19 | 富士通株式会社 | 半導体装置の製造方法及び製造装置 |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| AU2003263071B2 (en) | 2002-09-04 | 2007-03-15 | Merck Sharp & Dohme Llc | Pyrazolopyrimidines as cyclin-dependent kinase inhibitors |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| WO2004052286A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004082458A2 (en) | 2003-02-21 | 2004-09-30 | The Johns Hopkins University | Tyrosine kinome |
| JP2004277337A (ja) | 2003-03-14 | 2004-10-07 | Sumitomo Pharmaceut Co Ltd | ピラゾロ［１，５−ａ］ピリミジン誘導体 |
| US20070179161A1 (en) | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| WO2004089471A2 (en) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF |
| JP2006522744A (ja) | 2003-04-11 | 2006-10-05 | ノボ ノルディスク アクティーゼルスカブ | グルココルチコイド受容体アゴニスト療法に伴う副作用を最小化するための、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤およびグルココルチコイド受容体アゴニストを使用する併用療法 |
| US20060094699A1 (en) | 2003-04-11 | 2006-05-04 | Kampen Gita Camilla T | Combination therapy using an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist to minimize the side effects associated with glucocorticoid receptor agonist therapy |
| EP1619203A1 (en) | 2003-04-28 | 2006-01-25 | Galpharma Co., Ltd. | Galectin 9-inducing factor |
| PA8603801A1 (es) | 2003-05-27 | 2004-12-16 | Janssen Pharmaceutica Nv | Derivados de la quinazolina |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| EA009517B1 (ru) | 2003-06-27 | 2008-02-28 | Байер Кропсайенс Аг | Пиразолопиримидины |
| EA030259B8 (ru) | 2003-07-15 | 2018-09-28 | Амджен Инк. | Человеческие нейтрализующие антитела к фактору роста нервов (ngf) в качестве селективных ингибиторов метаболического пути ngf |
| US7491794B2 (en) | 2003-10-14 | 2009-02-17 | Intermune, Inc. | Macrocyclic compounds as inhibitors of viral replication |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| ES2305887T3 (es) | 2003-12-18 | 2008-11-01 | Janssen Pharmaceutica Nv | Derivados de pirido y pirimidopirimidinas como agentes antiproliferativos. |
| WO2005099363A2 (en) | 2004-03-26 | 2005-10-27 | Whitehead Institute For Biomedical Research | Methods of diagnosing, preventing and treating cancer metastasis |
| UA91677C2 (ru) | 2004-03-30 | 2010-08-25 | Интермюн, Инк. | Макроциклические соединения как ингибиторы вирусной репликации |
| JO3088B1 (ar) | 2004-12-08 | 2017-03-15 | Janssen Pharmaceutica Nv | مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف |
| DE102005003687A1 (de) | 2005-01-26 | 2006-07-27 | Sphingo Tec Gmbh | Immunoassay zur Bestimmung der Freisetzung von Neurotensin in die Zirkulation |
| CN101119996A (zh) * | 2005-02-16 | 2008-02-06 | 阿斯利康(瑞典)有限公司 | 化学化合物 |
| AU2006215394B2 (en) | 2005-02-16 | 2009-10-08 | Astrazeneca Ab | Chemical compounds |
| AU2006227300B2 (en) | 2005-03-21 | 2012-02-02 | Eli Lilly And Company | Imidazopyridazine compounds |
| JP2008540335A (ja) | 2005-04-27 | 2008-11-20 | アストラゼネカ・アクチエボラーグ | ピラゾリル・ピリミジン誘導体の疼痛治療における使用 |
| CA2608009A1 (en) | 2005-05-16 | 2006-11-23 | Astrazeneca Ab | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors |
| CN100406650C (zh) | 2005-06-05 | 2008-07-30 | 徐斌 | 一种抗特大变位的模块式梳型桥梁伸缩缝装置 |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| US20070025540A1 (en) | 2005-07-07 | 2007-02-01 | Roger Travis | Call center routing based on talkativeness |
| MX2008001166A (es) | 2005-07-25 | 2008-03-18 | Intermune Inc | Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c. |
| JP2009502734A (ja) * | 2005-07-29 | 2009-01-29 | アステラス製薬株式会社 | Ｌｃｋ阻害剤としての縮合複素環 |
| EP1909760A1 (en) | 2005-08-03 | 2008-04-16 | Eastman Chemical Company | Tocopheryl polyethylene glycol succinate powder and process for preparing same |
| US20070191306A1 (en) | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| AU2006283592A1 (en) | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| NZ566160A (en) | 2005-08-25 | 2010-12-24 | Creabilis Therapeutics Spa | Polymer conjugates of K-252A and derivatives thereof |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| EP1942900B1 (en) * | 2005-10-06 | 2015-06-03 | Merck Sharp & Dohme Corp. | Use of pyrazolo [1,5-a] pyrimidine derivatives for inhibiting kinases methods for inhibiting protein kinases |
| WO2007044407A2 (en) | 2005-10-06 | 2007-04-19 | Schering Corporation | Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors |
| EP1948633B1 (en) | 2005-10-11 | 2011-08-10 | Centre National De La Recherche Scientifique (Cnrs) | 3 -hydroxyflavone derivatives for the detection and the quantification of cell apoptosis |
| US8119592B2 (en) | 2005-10-11 | 2012-02-21 | Intermune, Inc. | Compounds and methods for inhibiting hepatitis C viral replication |
| EP1948663B1 (en) | 2005-10-21 | 2011-09-14 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase ii (ck2) modulators |
| GB0524436D0 (en) | 2005-11-30 | 2006-01-11 | Novartis Ag | Organic compounds |
| WO2007070504A2 (en) | 2005-12-13 | 2007-06-21 | Morton Grove Pharmaceuticals, Inc. | Stable and palatable oral liquid sumatriptan compositions |
| WO2007084815A2 (en) | 2006-01-19 | 2007-07-26 | Janssen Pharmaceutica, N.V. | Substituted thienopyrimidine kinase inhibitors |
| KR100846988B1 (ko) | 2006-03-06 | 2008-07-16 | 제일약품주식회사 | 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물 |
| US7723330B2 (en) | 2006-03-07 | 2010-05-25 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| GB0606805D0 (en) | 2006-04-04 | 2006-05-17 | Novartis Ag | Organic compounds |
| CL2007001165A1 (es) | 2006-04-26 | 2008-01-25 | Hoffmann La Roche | 2-(1h-indazol-4-il)-6-(4-metanosulfonil-piperazin-1-ilmetil)-4-morfolin-4-il-tieno[3,2-d]pirimidina; procedimiento de preparacion; composicion farmaceutica; proceso de preparacion de dicha composicion; kit farmaceutico; y uso para tratar enfermedades tales como cancer, desordenes inmunes y enfermedades cardiovasculares. |
| EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
| TW201345908A (zh) | 2006-07-05 | 2013-11-16 | Mitsubishi Tanabe Pharma Corp | 吡唑并〔１，５-ａ〕嘧啶化合物 |
| CA2659971A1 (en) | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Fused heterocyclic derivative and use thereof |
| WO2008016131A1 (fr) * | 2006-08-04 | 2008-02-07 | Takeda Pharmaceutical Company Limited | Composé hétérocyclique à cycles fusionnés |
| US7531539B2 (en) | 2006-08-09 | 2009-05-12 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| EP2063962A2 (en) | 2006-09-07 | 2009-06-03 | Biogen Idec MA Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
| CN101516885A (zh) * | 2006-09-29 | 2009-08-26 | 诺瓦提斯公司 | 作为pi3k脂质激酶抑制剂的吡唑并嘧啶类化合物 |
| RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
| SG176461A1 (en) | 2006-11-06 | 2011-12-29 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US7820684B2 (en) | 2007-03-01 | 2010-10-26 | Supergen, Inc. | Pharmaceutical formulations comprising salts of a protein kinase inhibitor and methods of using same |
| US20080234262A1 (en) | 2007-03-21 | 2008-09-25 | Wyeth | Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors |
| WO2008116898A1 (en) * | 2007-03-28 | 2008-10-02 | Biovitrum Ab (Publ) | Pyrazolo [1,5-a]pyrimidines as inhibitors of stearoyl-coa desaturase |
| DK2137184T3 (da) | 2007-04-03 | 2013-07-22 | Array Biopharma Inc | Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer |
| CN101720322A (zh) | 2007-05-04 | 2010-06-02 | Irm责任有限公司 | 作为c-kit和pdgfr激酶抑制剂的化合物和组合物 |
| CA2687909C (en) | 2007-06-21 | 2015-09-15 | Janssen Pharmaceutica Nv | Indolin-2-ones and aza-indolin-2-ones |
| CN103923072B (zh) | 2007-07-20 | 2017-05-31 | 内尔维阿诺医学科学有限公司 | 作为具有激酶抑制剂活性的取代的吲唑衍生物 |
| WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
| WO2009023540A1 (en) | 2007-08-10 | 2009-02-19 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| JP2011500702A (ja) | 2007-10-16 | 2011-01-06 | ワイス・エルエルシー | チエノピリミジンおよびピラゾロピリミジン化合物ならびにｍＴＯＲキナーゼおよびＰＩ３キナーゼ阻害剤としてのその使用 |
| CN101909647A (zh) | 2007-10-23 | 2010-12-08 | 诺瓦提斯公司 | TrkB抗体用于治疗呼吸病症的用途 |
| US20110046127A1 (en) | 2007-11-08 | 2011-02-24 | Paolo Pevarello | Imidazopyridazines for Use as Protein Kinase Inhibitors |
| WO2009070567A1 (en) | 2007-11-28 | 2009-06-04 | Schering Corporation | 2-fluoropyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| US8642035B2 (en) | 2008-01-17 | 2014-02-04 | Irm Llc | Anti-TrkB antibodies |
| EA018736B1 (ru) | 2008-03-03 | 2013-10-30 | Юсб Фарма, С.А. | Фармацевтические растворы, способ получения и терапевтическое применение |
| KR100963051B1 (ko) | 2008-03-14 | 2010-06-09 | 광동제약 주식회사 | 입자크기가 조절된 술포데히드로아비에트산을 함유한쓴맛이 저감된 경구용 액상 조성물 |
| US20090275622A1 (en) | 2008-04-30 | 2009-11-05 | Prasoona Linga | Nizatidine formulations |
| AU2009246687B2 (en) * | 2008-05-13 | 2012-08-09 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
| ES2532732T3 (es) | 2008-07-29 | 2015-03-31 | Nerviano Medical Sciences S.R.L. | Uso de un inhibidor de CDK para el tratamiento del glioma |
| PT2350075E (pt) | 2008-09-22 | 2014-06-09 | Array Biopharma Inc | Compostos imidazo[1,2b]piridazina substituídos como inibidores da trk cinase |
| DK3372605T3 (da) | 2008-10-22 | 2021-11-22 | Array Biopharma Inc | Substituerede pyrazol[1,5-a]pyrimidinforbindelser som trk-kinasehæmmere |
| CA2740792C (en) | 2008-10-31 | 2016-06-21 | Genentech, Inc. | Pyrazolopyrimidine jak inhibitor compounds and methods |
| CN102223885B (zh) | 2008-11-24 | 2013-04-03 | 内尔维阿诺医学科学有限公司 | 用于治疗间皮瘤的cdk抑制剂 |
| DK2881402T3 (en) | 2009-02-12 | 2017-08-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| NO3001903T3 (no) | 2009-12-21 | 2018-03-24 | ||
| US9161944B2 (en) | 2010-02-18 | 2015-10-20 | Inserm (Institut National De La Sante Et De La Sante Et De La Recherche Medicale) | Method for preventing cancer metastasis |
| BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
| US8383793B2 (en) | 2010-04-15 | 2013-02-26 | St. Jude Children's Research Hospital | Methods and compositions for the diagnosis and treatment of cancer resistant to anaplastic lymphoma kinase (ALK) kinase inhibitors |
| TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
| US8543395B2 (en) | 2010-05-18 | 2013-09-24 | Shazam Entertainment Ltd. | Methods and systems for performing synchronization of audio with corresponding textual transcriptions and determining confidence values of the synchronization |
| RU2735545C2 (ru) | 2010-05-20 | 2020-11-03 | Эррэй Биофарма Инк. | Макроциклические соединения в качестве ингибиторов киназы trk |
| KR101865426B1 (ko) | 2010-06-09 | 2018-07-13 | 다나-파버 캔서 인스티튜트 인크. | Raf와 mek 억제제에 대한 내성을 부여하는 mek1 돌연변이 |
| RS63063B1 (sr) | 2010-08-19 | 2022-04-29 | Zoetis Belgium S A | Anti-ngf antitela i njihova upotreba |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| CN103619879A (zh) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
| ES2551592T3 (es) | 2011-02-25 | 2015-11-20 | Novartis Ag | Pirazolo[1,5-a]piridinas como inhibidores de TRK |
| DK2712358T3 (en) | 2011-05-13 | 2017-02-06 | Array Biopharma Inc | PYRROLIDINYLUREA, PYRROLIDINYLTHIOUREA AND PYRROLIDINYLGUANIDE IN COMPOUNDS AS TRKA-KINASE INHIBITORS |
| WO2013059740A1 (en) | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
| CA2854936A1 (en) | 2011-11-14 | 2013-05-23 | Tesaro, Inc. | Modulating certain tyrosine kinases |
| EP2791138B1 (en) | 2011-12-12 | 2018-06-06 | Dr. Reddy's Laboratories Ltd. | Substituted pyrazolo[1,5-a]pyridine as tropomyosin receptor kinase (trk) inhibitors |
| WO2013161919A1 (ja) | 2012-04-26 | 2013-10-31 | 小野薬品工業株式会社 | Ｔｒｋ阻害化合物 |
| CA2873979C (en) | 2012-05-23 | 2019-11-12 | Nerviano Medical Sciences S.R.L. | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
| TWI585088B (zh) | 2012-06-04 | 2017-06-01 | 第一三共股份有限公司 | 作爲激酶抑制劑之咪唑并［１，２－ｂ］嗒衍生物 |
| KR20150023059A (ko) | 2012-06-28 | 2015-03-04 | 맥네일-피피씨, 인코포레이티드 | 라세카도트릴 액체 조성물 |
| EP2877598A1 (en) | 2012-07-24 | 2015-06-03 | Pharmacyclics, Inc. | Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk) |
| EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| CA2882759C (en) | 2012-08-31 | 2018-11-20 | The Regents Of The University Of Colorado | Detection of the ntrk1-mprip gene fusion for cancer diagnosis |
| US20140084039A1 (en) | 2012-09-24 | 2014-03-27 | Electro Scientific Industries, Inc. | Method and apparatus for separating workpieces |
| JP2014082984A (ja) | 2012-10-23 | 2014-05-12 | Astellas Pharma Inc | 新規ｎｔｒｋ２活性化変異の検出法 |
| PL2920166T3 (pl) | 2012-11-13 | 2017-05-31 | Array Biopharma, Inc. | Bicykliczne związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny przydatne w leczeniu bólu |
| WO2014078325A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-(monocyclic aryl),n'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9822118B2 (en) | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078328A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | N-bicyclic aryl,n'-pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| PL2922844T3 (pl) | 2012-11-13 | 2018-06-29 | Array Biopharma, Inc. | N-pirolidynyl, n’-pirazolilowe związki mocznika, tiomocznika, guanidyny i cyjanoguanidyny jako inhibitory kinazy trka |
| US9981959B2 (en) | 2012-11-13 | 2018-05-29 | Array Biopharma Inc. | Thiazolyl and oxazolyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| WO2014078417A1 (en) | 2012-11-13 | 2014-05-22 | Array Biopharma Inc. | Pyrazolyl urea, thiourea, guanidine and cyanoguanidine compounds as trka kinase inhibitors |
| US9969694B2 (en) | 2012-11-13 | 2018-05-15 | Array Biopharma Inc. | N-(arylalkyl)-N′-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9790178B2 (en) | 2012-11-13 | 2017-10-17 | Array Biopharma Inc. | Pyrrolidinyl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| CA2877847A1 (en) | 2012-11-29 | 2014-06-05 | Yeda Research And Development Co. Ltd. | Methods of preventing tumor metastasis, treating and prognosing cancer and identifying agents which are putative metastasis inhibitors |
| US9127055B2 (en) | 2013-02-08 | 2015-09-08 | Astellas Pharma Inc. | Method of treating pain with anti-human NGF antibody |
| TWI567068B (zh) | 2013-02-19 | 2017-01-21 | 小野藥品工業股份有限公司 | Ｔｒｋ抑制化合物 |
| US20160010068A1 (en) | 2013-02-22 | 2016-01-14 | Boris C. Bastian | Fusion polynucleotides and fusion polypeptides associated with cancer and particularly melanoma and their uses as therapeutic and diagnostic targets |
| WO2014134096A1 (en) | 2013-02-27 | 2014-09-04 | Oregon Health & Science University | Methods of treating cancers characterized by aberrent ros1 activity |
| WO2014150751A2 (en) | 2013-03-15 | 2014-09-25 | Novartis Ag | Biomarkers associated with brm inhibition |
| WO2014151734A1 (en) | 2013-03-15 | 2014-09-25 | The Trustees Of Columbia University In The City Of New York | Fusion proteins and methods thereof |
| WO2014151117A1 (en) | 2013-03-15 | 2014-09-25 | The Board Of Trustees Of The Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| WO2014152777A2 (en) | 2013-03-15 | 2014-09-25 | Insight Genetics, Inc. | Methods and compositions for the diagnosis and treatment of cancers resistant to ros1 inhibitors |
| US20140315199A1 (en) | 2013-04-17 | 2014-10-23 | Life Technologies Corporation | Gene fusions and gene variants associated with cancer |
| TWI610923B (zh) | 2013-07-11 | 2018-01-11 | Betta Pharmaceuticals Co Ltd | 酪氨酸蛋白激酶調節劑及其應用方法 |
| US10705087B2 (en) | 2013-07-26 | 2020-07-07 | Japanese Foundation For Cancer Research | Detection method for NTRK3 fusion |
| EP3628749A1 (en) | 2013-07-30 | 2020-04-01 | Blueprint Medicines Corporation | Ntrk2 fusions |
| JP6389884B2 (ja) | 2013-10-24 | 2018-09-12 | ジョージタウン・ユニバーシティＧｅｏｒｇｅｔｏｗｎ Ｕｎｉｖｅｒｓｉｔｙ | 癌を治療するための方法及び組成物 |
| WO2015064621A1 (ja) | 2013-10-29 | 2015-05-07 | 公益財団法人がん研究会 | 新規融合体及びその検出法 |
| SMT202300008T1 (it) | 2014-01-24 | 2023-03-17 | Turning Point Therapeutics Inc | Diaril macrociclici come modulatori di protein chinasi |
| PT3102555T (pt) | 2014-02-05 | 2021-06-04 | VM Oncology LLC | Composições de compostos e seus usos |
| US10231965B2 (en) | 2014-02-20 | 2019-03-19 | Ignyta, Inc. | Molecules for administration to ROS1 mutant cancer cells |
| EP3154959B1 (en) | 2014-05-15 | 2019-07-10 | Array Biopharma, Inc. | 1-((3s,4r)-4-(3-fluorophenyl)-1-(2-methoxyethyl)pyrrolidin-3-yl)-3-(4-methyl-3-(2-methylpyrimidin-5-yl)-1-phenyl-1h-pyrazol-5-yl)urea as a trka kinase inhibitor |
| WO2015183837A1 (en) | 2014-05-27 | 2015-12-03 | Brian Haynes | Compositions, methods, and uses related to ntrk2-tert fusions |
| US20170114415A1 (en) | 2014-05-30 | 2017-04-27 | The Regents Of The University Of Colorado, A Body Corporate | Activating ntrk1 gene fusions predictive of kinase inhibitor therapy |
| JP2017523188A (ja) | 2014-08-01 | 2017-08-17 | ファーマサイクリックス エルエルシー | Ｂｔｋ阻害剤を伴う治療に対するｄｌｂｃｌの応答を予測するためのバイオマーカー |
| TWI573794B (zh) | 2014-08-18 | 2017-03-11 | 小野藥品工業股份有限公司 | ＴｒＫ阻礙化合物之酸附加鹽 |
| UY36351A (es) | 2014-10-14 | 2016-06-01 | Novartis Ag | Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas |
| LT3699181T (lt) | 2014-11-16 | 2023-05-10 | Array Biopharma, Inc. | Kristalinė (s)-n-(5-((r)-2-(2,5-difluorfenil)-pirolidin-1-il)-pirazolo[1,5-a] pirimidin-3-il)-3 -hidroksipirolidino-1-karboksamido vandenilio sulfato forma |
| EP4420732A3 (en) | 2014-12-15 | 2024-11-27 | CMG Pharmaceutical Co., Ltd. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| CN104672121B (zh) | 2015-02-16 | 2017-10-24 | 上海华默西医药科技有限公司 | 2r‑(2,5‑二氟苯基)吡咯烷盐酸盐的制备方法 |
| BR112017024797A2 (pt) | 2015-05-20 | 2018-08-07 | The Broad Institute Inc. | neoantígenos partilhados |
| WO2016196141A1 (en) | 2015-05-29 | 2016-12-08 | Ignyta, Inc. | Compositions and methods for treating patients with rtk mutant cells |
| EP3303631A1 (en) | 2015-06-01 | 2018-04-11 | Loxo Oncology Inc. | Methods of diagnosing and treating cancer |
| AU2015101722A4 (en) | 2015-06-19 | 2016-05-19 | Macau University Of Science And Technology | Oncogenic ros1 and alk kinase inhibitor |
| US9782400B2 (en) | 2015-06-19 | 2017-10-10 | Macau University Of Science And Technology | Oncogenic ROS1 and ALK kinase inhibitor |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| US10316044B2 (en) | 2015-07-02 | 2019-06-11 | Tp Therapeutics, Inc. | Chiral diaryl macrocycles as modulators of protein kinases |
| EP3368039A1 (en) | 2015-10-26 | 2018-09-05 | The Regents of The University of Colorado, A Body Corporate | Point mutations in trk inhibitor-resistant cancer and methods relating to the same |
| WO2017127835A2 (en) | 2016-01-22 | 2017-07-27 | The Medicines Company | Aqueous formulations and methods of preparation and use thereof |
| JPWO2017155018A1 (ja) | 2016-03-11 | 2019-01-17 | 小野薬品工業株式会社 | Ｔｒｋ阻害剤抵抗性の癌治療剤 |
| HRP20241282T1 (hr) | 2016-04-04 | 2024-12-06 | Loxo Oncology, Inc. | Tečne formulacije (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid |
| US10045991B2 (en) | 2016-04-04 | 2018-08-14 | Loxo Oncology, Inc. | Methods of treating pediatric cancers |
| JP7057343B2 (ja) | 2016-04-04 | 2022-04-19 | ロクソ オンコロジー， インコーポレイテッド | 小児癌の処置方法 |
| MA44733A (fr) | 2016-04-19 | 2019-02-27 | Exelixis Inc | Procédé de traitement du cancer du sein négatif triple |
| US11214571B2 (en) | 2016-05-18 | 2022-01-04 | Array Biopharma Inc. | Process for the preparation of (S)-N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide and salts thereof |
| WO2017201156A1 (en) | 2016-05-18 | 2017-11-23 | Duke University | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab |
| JOP20190092A1 (ar) | 2016-10-26 | 2019-04-25 | Array Biopharma Inc | عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها |
| JOP20190213A1 (ar) | 2017-03-16 | 2019-09-16 | Array Biopharma Inc | مركبات حلقية ضخمة كمثبطات لكيناز ros1 |
| US20190247398A1 (en) | 2017-10-26 | 2019-08-15 | Array Biopharma Inc. | Formulations of a macrocyclic trk kinase inhibitor |
| WO2019191659A1 (en) | 2018-03-29 | 2019-10-03 | Loxo Oncology, Inc. | Treatment of trk-associated cancers |
-
2009
- 2009-10-21 DK DK18151233.6T patent/DK3372605T3/da active
- 2009-10-21 SI SI200932152T patent/SI3372605T1/sl unknown
- 2009-10-21 MY MYPI2011001770A patent/MY169791A/en unknown
- 2009-10-21 SG SG2014004790A patent/SG196855A1/en unknown
- 2009-10-21 KR KR1020147029018A patent/KR101652189B1/ko active IP Right Grant
- 2009-10-21 PL PL13197815.7T patent/PL2725028T3/pl unknown
- 2009-10-21 CN CN2009801518250A patent/CN102264736B/zh active Active
- 2009-10-21 TW TW107124940A patent/TWI670272B/zh active
- 2009-10-21 UA UAA201106366A patent/UA106054C2/uk unknown
- 2009-10-21 SG SG10201914059WA patent/SG10201914059WA/en unknown
- 2009-10-21 ES ES09740245.7T patent/ES2456346T3/es active Active
- 2009-10-21 RS RS20211578A patent/RS62869B1/sr unknown
- 2009-10-21 JP JP2011533303A patent/JP5600111B2/ja active Active
- 2009-10-21 PT PT97402457T patent/PT2350071E/pt unknown
- 2009-10-21 WO PCT/US2009/061519 patent/WO2010048314A1/en active Application Filing
- 2009-10-21 HU HUE16166461A patent/HUE037716T2/hu unknown
- 2009-10-21 PL PL16166461T patent/PL3106463T6/pl unknown
- 2009-10-21 SI SI200930889T patent/SI2350071T1/sl unknown
- 2009-10-21 NZ NZ592809A patent/NZ592809A/xx unknown
- 2009-10-21 TW TW098135670A patent/TWI458729B/zh active
- 2009-10-21 KR KR1020167022867A patent/KR101784798B1/ko active Protection Beyond IP Right Term
- 2009-10-21 AU AU2009308465A patent/AU2009308465B2/en active Active
- 2009-10-21 TW TW105143120A patent/TWI639605B/zh active
- 2009-10-21 TW TW103132675A patent/TWI577680B/zh not_active IP Right Cessation
- 2009-10-21 EP EP16166461.0A patent/EP3106463B3/en active Active
- 2009-10-21 RS RS20140151A patent/RS53247B/en unknown
- 2009-10-21 US US13/125,263 patent/US8513263B2/en active Active
- 2009-10-21 LT LTEP18151233.6T patent/LT3372605T/lt unknown
- 2009-10-21 AR ARP090104042A patent/AR074052A1/es active IP Right Grant
- 2009-10-21 ES ES16166461T patent/ES2669581T7/es active Active
- 2009-10-21 SG SG10201900514RA patent/SG10201900514RA/en unknown
- 2009-10-21 NO NO16166461A patent/NO3106463T3/no unknown
- 2009-10-21 EP EP09740245.7A patent/EP2350071B1/en active Active
- 2009-10-21 SI SI200931843T patent/SI3106463T1/en unknown
- 2009-10-21 KR KR1020187011433A patent/KR102037619B1/ko active IP Right Grant
- 2009-10-21 PT PT181512336T patent/PT3372605T/pt unknown
- 2009-10-21 ME MEP-2018-133A patent/ME03010B/me unknown
- 2009-10-21 DK DK09740245.7T patent/DK2350071T3/en active
- 2009-10-21 ES ES18151233T patent/ES2900243T3/es active Active
- 2009-10-21 PL PL09740245T patent/PL2350071T3/pl unknown
- 2009-10-21 LT LTEP16166461.0T patent/LT3106463T/lt unknown
- 2009-10-21 HU HUE13197815A patent/HUE030413T2/en unknown
- 2009-10-21 CN CN201310379854.0A patent/CN103509017B/zh active Active
- 2009-10-21 DK DK13197815.7T patent/DK2725028T3/en active
- 2009-10-21 HR HRP20211722TT patent/HRP20211722T1/hr unknown
- 2009-10-21 PL PL18151233T patent/PL3372605T3/pl unknown
- 2009-10-21 DK DK16166461.0T patent/DK3106463T6/da active
- 2009-10-21 KR KR1020177027624A patent/KR101853026B1/ko active IP Right Grant
- 2009-10-21 RS RS20180555A patent/RS57221B2/sr unknown
- 2009-10-21 PT PT131978157T patent/PT2725028T/pt unknown
- 2009-10-21 TR TR2018/07039T patent/TR201807039T4/tr unknown
- 2009-10-21 UY UY0001032192A patent/UY32192A/es active IP Right Grant
- 2009-10-21 SM SM20180244T patent/SMT201800244T1/it unknown
- 2009-10-21 CA CA2741313A patent/CA2741313C/en active Active
- 2009-10-21 ES ES13197815.7T patent/ES2588504T3/es active Active
- 2009-10-21 EP EP13197815.7A patent/EP2725028B1/en active Active
- 2009-10-21 KR KR1020117011561A patent/KR101634833B1/ko active Protection Beyond IP Right Term
- 2009-10-21 HU HUE18151233A patent/HUE057625T2/hu unknown
- 2009-10-21 SI SI200931507A patent/SI2725028T1/sl unknown
- 2009-10-21 MX MX2011004204A patent/MX2011004204A/es active IP Right Grant
- 2009-10-21 BR BRPI0919873A patent/BRPI0919873B8/pt active IP Right Grant
- 2009-10-21 EP EP18151233.6A patent/EP3372605B1/en active Active
- 2009-10-21 LT LTEP13197815.7T patent/LT2725028T/lt unknown
- 2009-10-21 PT PT161664610T patent/PT3106463T/pt unknown
-
2011
- 2011-04-14 IL IL212341A patent/IL212341A0/en unknown
- 2011-04-19 CL CL2011000880A patent/CL2011000880A1/es unknown
- 2011-05-16 CR CR20110261A patent/CR20110261A/es unknown
- 2011-05-20 CO CO11062725A patent/CO6440551A2/es active IP Right Grant
-
2012
- 2012-01-31 HK HK12100876.5A patent/HK1160640A1/xx unknown
-
2013
- 2013-07-16 US US13/943,590 patent/US8865698B2/en active Active
-
2014
- 2014-03-31 HR HRP20140309AT patent/HRP20140309T1/hr unknown
- 2014-06-30 JP JP2014134304A patent/JP5832597B2/ja not_active Expired - Fee Related
- 2014-07-02 HK HK14106634.3A patent/HK1193101A1/zh unknown
- 2014-09-18 US US14/490,460 patent/US9447104B2/en active Active
- 2014-10-21 SM SM201400153T patent/SMT201400153B/xx unknown
-
2015
- 2015-01-14 US US14/596,611 patent/US9127013B2/en active Active
- 2015-08-31 JP JP2015170033A patent/JP6105008B2/ja active Active
- 2015-09-04 US US14/846,166 patent/US9676783B2/en active Active
-
2016
- 2016-08-24 CY CY20161100831T patent/CY1118199T1/el unknown
- 2016-09-18 IL IL247884A patent/IL247884B/en active IP Right Grant
- 2016-09-20 JP JP2016182689A patent/JP6431512B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-05 US US15/399,389 patent/US10005783B2/en active Active
-
2018
- 2018-01-03 US US15/860,948 patent/US10047097B2/en active Active
- 2018-05-14 HR HRP20180746TT patent/HRP20180746T4/hr unknown
- 2018-05-18 CY CY20181100514T patent/CY1120260T1/el unknown
- 2018-07-25 US US16/044,653 patent/US10774085B2/en active Active
- 2018-08-29 RU RU2018131134A patent/RU2018131134A/ru unknown
- 2018-09-24 AR ARP180102740A patent/AR112833A2/es not_active Application Discontinuation
- 2018-11-02 JP JP2018207330A patent/JP6788649B2/ja active Active
-
2020
- 2020-03-10 NO NO2020004C patent/NO2020004I1/no unknown
- 2020-03-10 LT LTPA2020504C patent/LTC3106463I2/lt unknown
- 2020-03-10 NL NL301033C patent/NL301033I2/nl unknown
- 2020-03-11 LU LU00150C patent/LUC00150I2/fr unknown
- 2020-03-11 HU HUS2000006C patent/HUS000512I2/hu unknown
- 2020-03-16 CY CY2020006C patent/CY2020006I2/el unknown
- 2020-09-14 US US17/020,461 patent/US11267818B2/en active Active
- 2020-10-18 IL IL278119A patent/IL278119B/en unknown
-
2021
- 2021-11-26 CY CY20211101031T patent/CY1124923T1/el unknown
-
2022
- 2022-09-09 US US17/941,367 patent/US20230234955A1/en not_active Abandoned
-
2023
- 2023-03-28 US US18/191,283 patent/US20240132500A1/en active Pending